Unlike many biotech startups reliant on venture capital, Vivtex pursued a different path. By securing around 10 early pharma collaborations, the company generated a substantial stream of non-dilutive revenue, achieving profitability and financial independence far earlier than is typical.

Over 20 years, Alnylam raised $7.5 billion. Remarkably, this was evenly split between equity financing from capital markets and non-dilutive funding from pharmaceutical partnerships. This balanced strategy was essential for financing a long, capital-intensive R&D journey while managing shareholder dilution.

Vivtex funded its growth and reached profitability not through traditional VC rounds, but by securing around 10 early pharma partnerships. This strategy provided significant non-dilutive revenue, reducing their reliance on investors and giving them more control over their trajectory—a powerful alternative to the typical biotech funding model.

MRM Health's founder, Sam Possemiers, leveraged his profitable Contract Research Organization (CRO), Prodigest, to finance the entire seed stage of his new biotech venture. Reinvesting proceeds into technology development allowed MRM to de-risk its platform for five years without taking on early-stage dilutive funding.

While its internal pipeline targets oncology, LabGenius partners with companies like Sanofi to apply its ML-driven discovery platform to other therapeutic areas, such as inflammation. This strategy validates the platform's broad applicability while securing non-dilutive funding to advance its own assets towards the clinic.

Following positive data, ZymeWorks is shifting from a traditional R&D model to a diversified, royalty-based one. By partnering its own pipeline and acquiring external royalties, it aims to mitigate single-asset risk and return capital to shareholders via buybacks, a departure from the sector's typical cash-burn model.

Beyond developing its own drug portfolio, Monterosa strategically leverages its discovery platform for partnerships with companies like Roche and Novartis. These deals have provided over $300 million in non-dilutive capital, funding operations without giving away equity.

For pre-revenue biotechs like Voyager, partnering provides non-dilutive capital. More importantly, it de-risks development by sharing costs and leveraging a larger company's resources and expertise. This can increase a drug's probability of success, a crucial factor when most programs fail.

Candle Therapeutics secured $100M not through equity, but by selling a percentage of future US sales of its Phase III cancer therapy. This non-dilutive royalty financing provides capital for a product launch without giving up ownership, a strategic option for companies nearing FDA approval.